Home > Insider Trading > Filing (0000899243-22-034377)

Filing Details

Accession Number:: 0000899243-22-034377
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-10-27 21:50:11
Reporting Period:: 2022-10-25

Accepted Time:: 2022-10-27 21:50:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1404955	Loring Seth Harrison	C/O Akero Therapeutics, Inc., 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-10-25	4,515	$44.92	300,851	No	4	S	Direct
Common Stock	Disposition	2022-10-25	4,906	$44.92	326,813	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-10-26	35,860	$43.08	264,991	No	4	S	Direct
Common Stock	Disposition	2022-10-26	11,539	$43.97	253,452	No	4	S	Direct
Common Stock	Disposition	2022-10-26	18,486	$44.90	234,966	No	4	S	Direct
Common Stock	Disposition	2022-10-26	38,961	$43.08	287,852	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-10-26	12,537	$43.97	275,315	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-10-26	20,085	$44.90	255,230	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-10-27	40,903	$41.12	194,063	No	4	S	Direct
Common Stock	Disposition	2022-10-27	21,830	$42.03	172,233	No	4	S	Direct
Common Stock	Disposition	2022-10-27	3,693	$43.23	168,540	No	4	S	Direct
Common Stock	Disposition	2022-10-27	44,440	$41.12	210,790	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-10-27	23,719	$42.03	187,071	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2022-10-27	4,013	$43.23	183,058	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4.
The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution").
(Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution.
Represents shares held directly by the LLC. The reporting person is the manager of the LLC.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.635 to $45.14, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.715, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.72 to $42.715, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.495, inclusive.